Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Intuitive Surgical makes and sells surgical robots that help doctors perform operations with tiny cuts, and it earns most of its money from the instruments and service those robots need.
Intuitive Surgical builds the robots that let surgeons operate through cuts the size of a keyhole instead of slicing a patient open. Its main product is the da Vinci system: a machine with arms that hold tiny tools, which a surgeon controls from a console a few feet away. The surgeon sees a magnified, three-dimensional view and moves the robot's wrists with their hands, and the robot copies those movements inside the body with steadier precision than a human hand.
The company makes money in three connected ways. It sells the robot systems themselves, which can cost well over a million dollars each. But the bigger, more reliable stream comes from the disposable instruments and attachments that get used up in every operation — scissors, staplers, and the like — plus the service contracts that keep the machines running. This razor-and-blades setup is why hospitals that already own a da Vinci keep paying Intuitive year after year. A surgeon who trained on one system has little reason to switch, and hospitals have already sunk money into the machine and the training. The business took decades to build. The first da Vinci went into a hospital in the late 1990s, and growth was slow until the company proved the robots could handle prostate surgery and other delicate operations. Today its systems are used most heavily for prostate removal, hysterectomies, hernia repair, and increasingly for lung and other soft-tissue surgeries. Intuitive launched its newer da Vinci 5 system in 2024 to keep pushing the technology forward. Its main rivals are other surgical-robot makers, most notably Medtronic, which sells the Hugo system, plus Johnson & Johnson with its Ottava robot, though Intuitive remains far and away the market leader.
The company is enormously profitable, which gives it options. It spends heavily on research to stay ahead, has bought back large amounts of its own stock, and does not pay a dividend. The main risks are competition slowly chipping at its lead, hospitals pushing back on the cost of all those disposable instruments, and the simple fact that any high-priced capital equipment is vulnerable when hospital budgets tighten. That is why the recurring instrument and service revenue matters so much: it keeps the money coming in even when robot sales slow.
Saved answer · last researched 29 Oct 2026